Psychedelics in Medicine: Can Magic Mushrooms, LSD, and Ecstasy Offer New Hope to Those Struggles with Mental Health Conditions?
Substances such as magic mushrooms, ecstasy (MDMA), and LSD (acid) have been synonymous with the counterculture movement, rebellion, and illegal street use.
These substances were seen as reckless and dangerous.
Any connection of these substances and medical treatment was nonexistent.
In recent years, research has shown that this perception has is changing as scientists and doctors are exploring the potential therapeutic benefits of these substances, particularly for mental health disorders.
A revolutionary article in the Canadian Medical Association Journal (CMAJ) discusses the therapeutic effects of these substances that were once considered taboo.
Researchers shed light on the power of psychedelics like MDMA, psilocybin (the substance found in magic mushrooms or more commonly known as shrooms), and even LSD could be used to treat a whole host of mental health conditions.
Depression, anxiety, PTSD, and addiction to name a few. While research and funding are still in the early days, this shift in perception gives those that suffer from these conditions new hope on alternative treatments.
The History of Psychedelic Research
In the 1950s, the research of the use of psychedelic substances such as LSD and psilocybin as medical treatment began.
Research from this era have shown promising results for patients with deep-rooted psychological trauma and to help alleviate the suffering of terminally ill patients facing end-of life anxiety.
Unfortunately, these promising studies ended abruptly in the 1970s due to the mounting political pressure during the war on drugs.
As a result, research on psychedelics and their potential benefits stopped and the drugs in question became stigmatized and considered dangerous.
Despite this obstacle, various researchers from John Hopkins University and the University of British Columbia (UBC) have been advocating to restart the conversation surrounding psychedelics as a form of medical treatment.
This renewed interest in this research comes at critical time with society contending with the growing mental health crisis and limited treatment options available.
The Potential of Psychedelic Drugs in Mental Health Treatment
The research available in the CMAJ demonstrates how these substances show promising results in those struggling with mental health conditions.
Various participants report that psilocybin (the active ingredient in magic mushrooms), MDMA (the main compound in ecstasy), and LSD have helped them feel more grounded, enhance their well-being, and help them navigate through their traumas.
Psilocybin: A Beacon of Hope for Addiction and Anxiety
The most exciting aspect of the current research available is the use of psilocybin in treating addiction and anxiety.
Numerous individuals have stated that psilocybin has helped them relive the symptoms of their depression and anxiety.
The results were remarkable with many patients reporting lasting reductions in their anxiety and an enhanced sense of well-being.
A recent study focused particularly on tobacco users and found that psilocybin therapy resulted in an 80% success rate after six months.
This extraordinary success rate exceeds the success rates of conventional treatments such as nicotine replacement therapies or other smoking termination programs.
These findings give new hope as a relatively safe and highly effective treatment option to those struggling with addiction.
MDMA: PTSD and Healing Trauma
Traditionally viewed as a party drug, MDMA, commonly referred to as ecstasy, is now considered a potential treatment for individuals suffering from PTSD.
PTSD, which can affect anyone at varying levels are more common with veterans, first responders, and other patients who have experienced severe trauma.
PTSD is disreputably difficult to treat with traditional methods and therapies.
However, in recent years, clinical trials have shown MDMA-assisted psychotherapy have helped patients heal form psychological wounds and confront traumatic memories.
Various studies were conducted in Vancouver with former soldiers and first responders.
The studies consisted of MDMA-assisted psychotherapy and had shown promising results in the early stages.
Numerous patients reported significant reduction in their PTSD symptoms and episodes after a handful of sessions.
The therapeutic use of MDMA is believed to work by promoting emotional openness which in turn enhances the therapeutic process of processing and discussing difficult emotions associated with their PTSD.
This has been reported to enhance and improve the conventional talk therapy that is more widely used as treatment.
LSD and Other Psychedelics: Breaking the Cycle of Addiction and Anxiety
While psilocybin and MDMA are more commonly used in psychedelic research, other substances such as LSD and ayahuasca are being studied for their potential therapeutic uses.
Ayahuasca is a powerful hallucinogenic brew that is used in traditional amazonian shamanic rituals.
This intense hallucinogenic has the potential to help individuals break free from addictions.
Individuals who have participated in ayahuasca ceremonies have stated that they experienced a lasting sense of clarity and peace as well as profound psychological breakthroughs.
Ensuring Safe Use in Clinical Trials
As with any treatment available, traditional or with psychedelics, there are risks considering.
Psychedelics can potentially have negative effects for individuals with a predisposition to mental health disorders like bipolar disorder or psychosis.
For these individuals, there is a risk that psychedelics can trigger a psychotic break.
To mitigate these risks, clinical trials must emphasize the importance of pre-screening participants to ensure they are suitable to partake in psychedelic therapy.
Equally, patients need to be closely monitored throughout the treatment process with medical professionals and licensed therapists to help manage any adverse effects.
The Future of Psychedelic Research
Despite all the potential promising benefits of psychedelics as a therapy, there are still significant hurdles that researchers face.
Unfortunately, these substances are still stigmatized and illegal in many parts of the world.
And because of the taboo surrounding these substances, researchers, funding bodies, and policymakers may feel reluctant to pursue further research on these potentially therapeutic tools.
Thanks to mechanisms within Health Canada, researchers have been able to study illegal substances like MDMA and psilocybin under strict regulatory conditions.
This has allowed for the development of clinical trials like the B.C. study on MDMA-assisted psychotherapy, which received approval even under the conservative government’s tough stance on drugs.
Unfortunately, the future of psychedelic medicine will depend on the public and policymakers’ perception and assumptions about these substances.
As well as continued research and accumulation of positive clinical data.
As these factors change, we may see a shift in how we approach mental health treatment with psychedelics potentially playing a key role in future care.
Conclusion
Psychedelics were once considered dangerous and even to this day, some view them as such.
As research continues, psychedelics can become a stepping stone for modern mental health treatments. The potential benefits of these substances in treating PTSD, depression, anxiety, and many more are increasingly harder to ignore.
The hope is that with the right regulatory frameworks in place, we can see a future where these substances are used to treat those that are suffering from these mental health conditions.
